requirements for this prospectus and future filings.We have granted the underwriters an option for a period of 30 days to purchase an additional 705,000 shares of common stock.Certain of our existing institutional investors, including investors affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of up to
this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.•Our business currently depends substantially on the success of CPI-444, which will require significant clinical testing before we can
If we are unable to obtain regulatory approval for, or successfully commercialize, CPI-444, our business will be materially harmed.•Any termination or suspension of, or delays in the commencement or completion of, our planned clinical trials could result in
increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.•All of our product candidates are still in preclinical or early-stage clinical development.
we may initiate based on the results of our planned clinical trials or discussions with the FDA, including any additional trials the FDA or other regulatory agencies may require;•the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;•the costs and timing of obtaining or maintaining manufacturing for CPI-444 and our other product candidates, including commercial
manufacturing if any product candidate is approved;•the costs and timing of establishing sales and marketing capabilities and enhanced internal controls over financial reporting;•our ability to achieve sufficient market acceptance, coverage and reimbursement from third-party payors and adequate market share for
If we are unable to obtain regulatory approval for, or successfully commercialize, CPI-444, our business will be materially harmed.Our product candidates are in the early stage of development and will require additional preclinical studies, substantial clinical
the future regulatory and commercial success of CPI-444 is subject to a number of risks, including the following:•we may not have sufficient financial and other resources to complete the necessary clinical trials for CPI-444;•we may not be able to demonstrate evidence of efficacy and safety for CPI-444 to the satisfaction of regulatory authorities;•the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or comparable
foreign regulatory bodies for marketing approval;•subjects in our clinical trials may die or suffer other adverse effects for reasons that may or may not be related to CPI-444;•we do not know the degree to which CPI-444 will be accepted as a therapy, even if approved; and•we may not be able to obtain, maintain or enforce our patents and other intellectual property rights.Of
clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.Before we can initiate clinical trials in the United States for our product candidates, we must submit the results of preclinical
reasons, including delays related to:•the FDA failing to grant permission to proceed or placing the clinical trial on hold;•subjects failing to enroll or remain in our trial at the rate we expect;•subjects choosing an alternative treatment for the indication for which we are developing CPI-444 or other product candidates, or
is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and
obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates.If we encounter difficulties enrolling subjects in our clinical trials, our clinical development
post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business, prospects, operating results and financial condition.During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their
would be costly and time-consuming and delay or permanently halt our development of CPI-444 or any other product candidates.18Table of ContentsRisks Related to Our Reliance on Third PartiesWe expect to rely on third parties to conduct our clinical trials.
product candidates;•managing the complexity of our clinical trial designs;•receipt of marketing approvals from the FDA and similar foreign regulatory authorities;•establishing commercial manufacturing capabilities by making arrangements with third-party manufacturers;•successfully launching commercial sales of any approved products, whether alone or in collaboration with others;•acceptance of any approved products by patients, the medical community and third-party payors;•establishing market share while competing with other therapies;•a continued acceptable safety profile of any approved products;•maintaining compliance with post-approval regulation and other requirements; and•qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering our
be subject to additional regulatory burdens and other risks and uncertainties.Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets.
regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries.Governments may impose price controls, which may adversely affect our future profitability.We intend to seek approval to market our product candidates in both the United States and in foreign jurisdictions.